Boehringer Ingelheim
PharmaIngelheim am Rhein, Germany, Germany · Est. 1885 · 52,000 employees
Boehringer Ingelheim is a privately-held pharmaceutical company developing innovative medicines across respiratory, oncology, cardiovascular, and immunological therapeutic areas.
12
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
15
Indications↗
Distinct diseases across all programs
2,273
Clinical Trials↗
All sponsored trials (all statuses)
80
Orange Book Patents
Across 12 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
12 drugs in development
Approved1
Phase 32
Phase 22
Phase 18
Preclinical3
By Therapeutic Area
top 4
Oncology
969%
Dermatology
215%
Respiratory
18%
Immunology
18%
R&D Momentum
89/100
Pipeline Velocity
76/100
Trial Completion Rate
91/100
Pipeline Concentration
51/100
Pipeline Freshness
77/100
Strategic Signals
- ↗Active in Dermatology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Nov 3, 2026
Recruiting
Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations
Nov 3, 2026
Completed
Pharmacokinetics, Safety and Tolerability of Zongertinib Following Oral Administration in Male and Female Participants of Non-childbearing Potential With Different Degrees of Hepatic Impairment (Child-Pugh Classification A and B) Compared With Matched Male and Female Participants of Non-childbearing Potential With Normal Hepatic Function (an Open-label, Non-randomised, Single-dose, Parallel, Individual-matched Design Trial)
Nov 3, 2026
Recruiting
Phase Ia, First in Human Open Label Dose Escalation Trial Evaluating Intravenous BI 1703880 in Combination With Intravenous Ezabenlimab for Treatment of Advanced Solid Tumours
Oct 31, 2026
Recruiting
A First-in-human, Phase I, Open-label, Non-randomized, Multicentre Dose Escalation and Expansion Trial of BI 3810944 in Patients With Solid Tumours and Melanoma
Oct 30, 2026
Recruiting
A Phase III, Randomised, Double-blind, Parallel-group, 56-week Study, Evaluating the Efficacy and Safety of Survodutide (BI 456906), Compared With Placebo, in Participants With Type 2 Diabetes, as an Adjunct to Diet and Physical Activity Alone or in Combination With Either Oral Antidiabetic Medications or Insulin
Oct 30, 2026
Completed
A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity With Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVD
Oct 30, 2026
Terminated
1-yr Study Comparing TioSal Combo Regimens Versus Single Agent Therapies (Spiriva HandiHaler and Salmeterol PE Capsule)
Details
Company Info
Company Overview
—
Mkt Cap
$23.8B
Revenue
—
Cash
CEOHubertus von Baumbach
Founded1885
Employees52,000
HQIngelheim am Rhein, Germany, Germany
Websiteboehringer-ingelheim.com
LinkedInCompany Page
Therapeutic Focus
respiratory diseasesoncologycardiovascular diseaseimmunology
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Dermatology(2 drugs)
2
—
—
—
1
Dermatology(2 drugs)
Immunology(1 drug)
1
—
—
—
—
Immunology(1 drug)
Oncology(9 drugs)
1
8
2
1
—
Oncology(9 drugs)
Respiratory(1 drug)
—
—
—
1
—
Respiratory(1 drug)
Regulatory
Regulatory Timeline
202512 events
FDADec 22
dextromethorphan hydrobromide — MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM
Application NDA217338
FDADec 4
Catapres — CATAPRES-TTS-3, CATAPRES-TTS-1, CATAPRES-TTS-2
Application NDA018891
FDANov 5
dextromethorphan hydrobromide — AUVELITY
Application NDA215430
FDAOct 29
Ketalar — KETALAR
Application NDA016812
FDAOct 23
Catapres — JAVADIN
Application NDA220256 (NDA)
FDAOct 21
Spevigo — SPEVIGO
Application BLA761244
FDAOct 7
Jascayd — JASCAYD
Application NDA218764 (NDA)
FDAAug 8
Hernexeos — HERNEXEOS
Application NDA219042 (NDA)
FDAJun 17
Pradaxa — PRADAXA
Application NDA022512
FDAJun 17
Pradaxa — PRADAXA
Application NDA214358
FDAJun 5
Anjeso — XIFYRM
Application NDA218395 (NDA)
FDAJun 5
Vivlodex — XIFYRM
Application NDA218395 (NDA)
20268 events
FDAJul 28
Catapres — QLONILIK
Application NDA221094 (NDA)
FDAJun 23
dextromethorphan hydrobromide — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE
Application ANDA220869
FDAJun 3
dextromethorphan hydrobromide — DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE
Application ANDA204196
FDAApr 30
dextromethorphan hydrobromide — AUVELITY
Application NDA215430
FDAApr 30
dextromethorphan hydrobromide — AUVELITY
Application NDA215430
FDAMar 23
Ketalar — KETALAR
Application NDA016812
FDAMar 20
Ketalar — KETALAR
Application NDA016812
FDAMar 12
dextromethorphan hydrobromide — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE
Application ANDA218264
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)